Analysts Set Savara Inc (NASDAQ:SVRA) Price Target at $9.86

Savara Inc (NASDAQ:SVRA) has been given an average rating of “Moderate Buy” by the seven brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $9.86.

SVRA has been the topic of a number of analyst reports. Evercore ISI reiterated an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. HC Wainwright reduced their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Thursday, December 19th. Finally, Wells Fargo & Company started coverage on Savara in a report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company.

Savara Stock Performance

SVRA opened at $2.69 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara has a fifty-two week low of $2.59 and a fifty-two week high of $5.70. The firm has a market capitalization of $461.66 million, a price-to-earnings ratio of -6.26 and a beta of 0.63. The company’s 50 day moving average price is $2.93 and its two-hundred day moving average price is $3.55.

Insider Activity at Savara

In other Savara news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Vestal Point Capital LP lifted its holdings in Savara by 33.2% during the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock worth $33,079,000 after acquiring an additional 2,685,000 shares during the period. Rosalind Advisors Inc. bought a new stake in Savara in the fourth quarter worth about $8,151,000. Nantahala Capital Management LLC raised its position in Savara by 45.2% in the fourth quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock worth $23,103,000 after acquiring an additional 2,344,308 shares during the period. Emerald Advisers LLC bought a new stake in shares of Savara in the 4th quarter worth approximately $7,161,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Savara by 49.9% in the 4th quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company’s stock worth $20,983,000 after purchasing an additional 2,275,000 shares during the period. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.